CARGO Therapeutics Publishes Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy In The Lancet

7/10/24 8:01:55 AM ET

$CRGX

Get the next $CRGX alert in real time by email

Ongoing Phase 1 study informed dose selection for CARGO's currently enrolling, potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel)1, in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL)
Notable patient subset analyses show durability of Complete Response (CR), underscoring promising efficacy in a high-risk, heavily pretreated population with advanced disease
- Most recent, longer-term follow-up data for Stanford Medicine's Phase 1 presented at the 2024 European Hematology Association (EHA) Congress, continued to show promising efficacy, durability and safety profile of firi-cel

Get the next $CRGX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CRGX

Date	Price Target	Rating	Analyst
7/22/2024	$33.00	Buy	H.C. Wainwright
7/8/2024	$28.00	Buy	Chardan Capital Markets
6/27/2024	$37.00	Overweight	Piper Sandler
12/5/2023	$34.00	Buy	Truist
12/5/2023	$28.00	Buy	Jefferies
12/5/2023	$23.00	Overweight	JP Morgan
12/5/2023		Outperform	TD Cowen

More analyst ratings

CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- 57 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel); on track for interim analysis in 1H25 - - CRG-023 pre-clinical data to be presented at ASH 2024; IND submission anticipated Q1'25 with Phase 1 initiation planned for 2025 - - Anup Radhakrishnan, CFO of CARGO Therapeutics, appointed as COO and CFO - SAN CARLOS, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell therapies for cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided a
11/12/24 4:05:00 PM ET
$CRGX
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
– Appointment adds strategic finance and broad operating experience to Board as Company advances potentially pivotal Phase 2 clinical study for CAR T-cell therapy candidate, firicabtagene autoleucel (firi-cel) – SAN CARLOS, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Jane Pritchett Henderson to its Board of Directors. Ms. Henderson will also serve as a member of the audit and compensation committees. "Jane's appointment exemplifies CARGO's ongoing commitment to strong corporate g
6/4/24 4:05:00 PM ET
$CRGX
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022); Currently on-track for interim results expected in 1H25 - - Independent Data Monitoring Committee (IDMC) recommended continuation of FIRCE-1 without modifications - - Ongoing follow-up from the Stanford Phase 1 study for firi-cel1 to be presented at the 2024 European Hematology Association (EHA) Congress, highlighting median overall survival of 25.7 months and favorable safety profile at the dose level selected for CARGO's Phase 2 Study - SAN CARLOS, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ
5/14/24 4:05:00 PM ET
$CRGX

CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- 57 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel); on track for interim analysis in 1H25 - - CRG-023 pre-clinical data to be presented at ASH 2024; IND submission anticipated Q1'25 with Phase 1 initiation planned for 2025 - - Anup Radhakrishnan, CFO of CARGO Therapeutics, appointed as COO and CFO - SAN CARLOS, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell therapies for cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided a
11/12/24 4:05:00 PM ET
$CRGX
CARGO Therapeutics to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will be participating in the following investor conferences. Jefferies London Healthcare Conference Gina Chapman, President and Chief Executive Officer, is scheduled to participate in a fireside chat on Wednesday, November 20, at 11:00 a.m. GMT / 3:00 a.m. PST, in London, UK. Piper Sandler 36th Annual Healthcare Conference Gina Chapman, President and Chief Executive Officer, is scheduled to participate in a fireside chat on We
11/5/24 4:05:00 PM ET
$CRGX
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity
- CRG-023 is a CD19-, CD20-, CD22-targeting tri-specific CAR T product candidate designed with the goal of providing more patients with a broad range of B-cell malignancies with durable responses by addressing several known causes of relapse, resulting in a potential best-in-class CAR T-cell therapy - - First of its kind, tri-cistronic CAR T to express three independent CARs from a single vector, with each CAR having a distinct co-stimulatory domain – - Data demonstrated sustained anti-tumor activity and a lack of functional exhaustion during repeated challenge from tumor cells, preservation of T cell memory phenotype relative to controls, sustained tumor clearance when only a single antig
11/5/24 9:23:06 AM ET
$CRGX

CARGO Therapeutics Publishes Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy In The Lancet

Chat with this insight

Recent Analyst Ratings for
$CRGX

$CRGX
SEC Filings

SEC Form 424B3 filed by CARGO Therapeutics Inc.

SEC Form 10-Q filed by CARGO Therapeutics Inc.

CARGO Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$CRGX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on CARGO Therapeutics with a new price target

Chardan Capital Markets initiated coverage on CARGO Therapeutics with a new price target

Piper Sandler initiated coverage on CARGO Therapeutics with a new price target

$CRGX
Leadership Updates

Live Leadership Updates

$CRGX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director

CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Amendment: SEC Form SC 13G/A filed by CARGO Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by CARGO Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by CARGO Therapeutics Inc.

$CRGX
Market Insights

Live Market Insights

HC Wainwright & Co. Initiates Coverage On Cargo Therapeutics with Buy Rating, Announces Price Target of $33

CARGO Therapeutics Publishes Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy In The Lancet

Chardan Capital Initiates Coverage On Cargo Therapeutics with Buy Rating, Announces Price Target of $28

$CRGX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Officer Radhakrishnan Anup

President & CEO Chapman Gina exercised 10,141 shares at a strike of $5.03 and sold $254,232 worth of shares (10,141 units at $25.07) (SEC Form 4)

Chief Financial Officer Radhakrishnan Anup exercised 1,600 shares at a strike of $5.03 and sold $40,452 worth of shares (1,600 units at $25.28) (SEC Form 4)

$CRGX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Samsara Biocapital Gp, Llc bought $4,998,000 worth of shares (294,000 units at $17.00) (SEC Form 4)

$CRGX
Press Releases

Fastest customizable press release news feed in the world

CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

CARGO Therapeutics to Participate in Upcoming Investor Conferences

CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity

CARGO Therapeutics Publishes Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy In The Lancet

Chat with this insight

Recent Analyst Ratings for $CRGX

$CRGX SEC Filings

SEC Form 424B3 filed by CARGO Therapeutics Inc.

SEC Form 10-Q filed by CARGO Therapeutics Inc.

CARGO Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$CRGX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on CARGO Therapeutics with a new price target

Chardan Capital Markets initiated coverage on CARGO Therapeutics with a new price target

Piper Sandler initiated coverage on CARGO Therapeutics with a new price target

$CRGX Leadership Updates

Live Leadership Updates

$CRGX Large Ownership Changes

This live feed shows all institutional transactions in real time.

CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director

CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Amendment: SEC Form SC 13G/A filed by CARGO Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by CARGO Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by CARGO Therapeutics Inc.

$CRGX Market Insights

Live Market Insights

HC Wainwright & Co. Initiates Coverage On Cargo Therapeutics with Buy Rating, Announces Price Target of $33

CARGO Therapeutics Publishes Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy In The Lancet

Chardan Capital Initiates Coverage On Cargo Therapeutics with Buy Rating, Announces Price Target of $28

$CRGX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Officer Radhakrishnan Anup

President & CEO Chapman Gina exercised 10,141 shares at a strike of $5.03 and sold $254,232 worth of shares (10,141 units at $25.07) (SEC Form 4)

Chief Financial Officer Radhakrishnan Anup exercised 1,600 shares at a strike of $5.03 and sold $40,452 worth of shares (1,600 units at $25.28) (SEC Form 4)

$CRGX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Samsara Biocapital Gp, Llc bought $4,998,000 worth of shares (294,000 units at $17.00) (SEC Form 4)

$CRGX Press Releases

Fastest customizable press release news feed in the world

CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

CARGO Therapeutics to Participate in Upcoming Investor Conferences

CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity

Recent Analyst Ratings for
$CRGX

$CRGX
SEC Filings

$CRGX
Analyst Ratings

$CRGX
Leadership Updates

$CRGX
Large Ownership Changes

$CRGX
Market Insights

$CRGX
Insider Trading

$CRGX
Insider Purchases

$CRGX
Press Releases